Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differencesDeveloping a Laboratory Model of Smoking Lapse Targeting Stress and Brief Nicotine Deprivation
Oberleitner LMS, Moore KE, Verplaetse T, Roberts W, McKee SA. Developing a Laboratory Model of Smoking Lapse Targeting Stress and Brief Nicotine Deprivation. Experimental And Clinical Psychopharmacology 2018, 26: 244-250. PMID: 29863382, PMCID: PMC5990030, DOI: 10.1037/pha0000187.Peer-Reviewed Original ResearchConceptsNicotine deprivationAd libitum smokingSmoking lapse behaviorHuman laboratory modelImagery inductionSmoking periodOnly significant differenceDaily smokersTobacco cravingMonetary reinforcementSmokingSeparate daysHuman laboratoryLapse behaviorSignificant differencesMood statesEffects of stressReduced abilityDelay periodNegative mood statesPrimary aimStress imagerySecondary goalCurrent studyNeutral imagery